Form 4: Jasper Therapeutics CEO Granted 500,000 Stock Options

Jasper Therapeutics' CEO and President, Jeetinder Singh Mahal, was granted 500,000 stock options with an exercise price of $1.35, vesting over several years.

Summary

• Jeetinder Singh Mahal, CEO, President, and Director of Jasper Therapeutics, Inc. (JSPR), was granted 500,000 stock options.
• The options have an exercise price of $1.35 per share.
• The transaction date for the grant was February 6, 2026.
• The options expire on February 6, 2036.
• Vesting schedule: 1/4th of the shares vest on February 6, 2027, and 1/48th of the original number of shares vest each month thereafter, contingent on continuous service.
• Following this transaction, Mahal beneficially owns 500,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns the CEO's incentives with long-term shareholder value, which is generally favorable for corporate governance and performance, though it also represents potential future dilution.

Positives

• The grant of 500,000 stock options to the CEO aligns management's incentives with long-term shareholder value creation.
• The vesting schedule encourages continuous service and commitment from the CEO.

Negatives

• The exercise price of $1.35 indicates that the stock price needs to rise above this level for the options to be in-the-money, representing a potential dilution if exercised and the stock price increases significantly.

Future Outlook

The stock options are subject to a vesting schedule, with 1/4th vesting on February 6, 2027, and the remainder vesting monthly thereafter, contingent on the CEO's continuous service to the company. This structure aims to incentivize long-term performance and retention.

Industry Context

StockSavvy.ai notes that granting stock options to executive leadership is a standard practice in the biotechnology and pharmaceutical industries, particularly for companies like Jasper Therapeutics, which are often in development stages. This compensation structure is designed to align executive interests with long-term company growth and shareholder returns, especially given the inherent risks and long development cycles in the sector.

Comparison to Industry Standards

• The grant of 500,000 options to a CEO of a company like Jasper Therapeutics is within typical ranges for executive compensation in the biotech sector, comparable to grants seen at similar-stage companies such as CRISPR Therapeutics or Editas Medicine, where equity forms a significant portion of total compensation.
• The 10-year expiration period (until 2036) is standard for employee stock options, providing a long-term incentive horizon.
• The four-year vesting schedule (one-year cliff followed by monthly vesting) is a common industry practice to ensure executive retention and incentivize sustained performance.

Related Party Transactions

• The stock option grant to the CEO is a related party transaction, as it involves compensation to an executive officer and director.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the CEO's incentives lead to increased stock price, but also potential for dilution if options are exercised.
• Employees: No direct impact mentioned, but a well-incentivized CEO can positively influence overall company performance and employee morale.

Next Steps

• The stock options will begin vesting on February 6, 2027, with 1/4th of the shares.
• Subsequent vesting will occur monthly (1/48th of original shares) following the initial cliff, subject to continuous service.
• The CEO may exercise these options at any time after vesting and before the expiration date of February 6, 2036.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (stock option grant) and does not contain information that would fundamentally alter the investment thesis for Jasper Therapeutics. While it aligns management incentives, it's not a catalyst for a "buy" or "sell" recommendation on its own. Investors should continue to hold and monitor the company's operational and financial performance.

Keywords

Jasper Therapeutics, JSPR, Stock Option, CEO Compensation, Executive Compensation, Form 4, Insider Transaction, Equity Grant, Vesting Schedule